Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Melanocytes Found To Contain Olfactory Receptor

XTALKS VITALS NEWS

Skin Cancer

The receptor – which is activated by the olfactory molecule beta-ionone – could be play a role in the development of skin cancer.

Share this!

June 3, 2016 | by Sarah Massey, M.Sc.

Researchers in Germany have identified a specialized scent receptor in the pigment-producing cells of the skin, known as melanocytes. The receptor – which is activated by the olfactory molecule beta-ionone – could be play a role in the development of skin cancer. Tweet: Researchers identified a scent receptor in #melanocytes http://ctt.ec/18c7c+

Using human melanocyte cell cultures, the researchers identified an olfactory receptor known as 51E2. The melanocytes are responsible for producing melanin, a pigment that is released in response to sun exposure and other environmental skin stressors. If melanocytes begin to exhibit signs of unregulated growth however, the excess pigmentation could trigger the development of skin cancer.

In their article, the researchers from Ruhr-Universität Bochum in Germany present the details of the 51E2 olfactory receptor. If the correct odorant binds to the melanocyte’s receptor, a signaling cascade is triggered which increases the cellular concentration of calcium ions.



These calcium ions continue the signaling pathway, at the end of which phosphate groups are transferred to proteins known as MAP-kinases. By regulating enzyme activity, this receptor reaction modulates cell growth and production of melanin.

According to the researchers, the pathway shares similarities to that which occurs when a scent molecular binds to an olfactory receptor in the human nose. The results of this research were published in the Journal of Biological Chemistry.

“The receptor and its activating odor molecule might constitute a new starting point for a melanoma therapy,” said Dr. Hanns Hatt of Bochum's Department for Cell Physiology. While cancerous melanocytes put much of their energy into rapid proliferation, they often stop performing their normal functions which can be influenced by the beta-ionone odorant receptor.

Hatt and his colleagues are currently studying the role of this receptor in melanoma cells collected from patient biopsies. “With its help, we might be able to treat pigmentation disorders of the skin, and they might also be used in tanning products,” said Hatt.


Keywords: Skin Cancer, Melanocytes, Signaling Pathway


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.